Citation: Journal of Oncology Pharmacy Practice. :1078155218800147, 2018 Sep 26.Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.Published: ; 2018ISSN: 1078-1552.Full author list: Vakiti A; Cho MH; Lee W; Liang JJ; Lalos AT; Fishbein DA.UI/PMID: 30253731.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Internal Medicine | Pathology | Medicine/Gastroenterology | Transplant Hepatology Service | Medicine/Infectious DiseasesActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1177/1078155218800147 (Click here)Abbreviated citation: J Oncol Pharm Pract. :1078155218800147, 2018 Sep 26.Abstract: Hepatitis C viral infection is recognized worldwide as a leading cause of cirrhosis and hepatocellular carcinoma. The goal of hepatitis C viral antiviral therapy is the permanent eradication of hepatitis C viral RNA, commonly referred to as a sustained virologic response - defined as "undetectable" RNA at 12 weeks following the completion of therapy. Hepatitis C viral treatment has dramatically advanced with the FDA approval of several new agents known as direct-acting antivirals. These drugs target specific nonstructural proteins of the virus, which disrupt viral replication, and therefore halt infection. However, recently, there has been a concern for increased risk of recurrence of treated hepatocellular carcinoma or denovo occurrence of hepatocellular carcinoma after treatment with direct-acting antivirals. We are now reporting three cases of intrahepatic cholangiocarcinoma that developed after sustained virologic response following hepatitis C viral treatment with direct-acting antivirals.